Ryan M Carey1, Alan D Workman1, Bei Chen2, Nithin D Adappa2, James N Palmer2, David W Kennedy2, Robert J Lee2, Noam A Cohen2,3. 1. Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA. 2. Department of Otorhinolaryngology-Head and Neck Surgery, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA. 3. Philadelphia Veterans Administration Medical Center Surgical Services, Philadelphia, PA.
Abstract
BACKGROUND: Nitric oxide (NO) is an important antibacterial defense molecule produced by upper airway (sinonasal) epithelial cells. We previously showed that a bitter taste receptor expressed in airway epithelium detects quorum-sensing molecules secreted by Gram-negative bacteria and subsequently triggers bactericidal NO production. We hypothesized that the upper airway epithelium may also be able to detect the Gram-positive aerobe Staphylococcus aureus and mount an NO response. METHODS: Human sinonasal air-liquid interface (ALI) cultures were treated with methicillin-resistant S. aureus (MRSA)-conditioned medium (CM), and NO production was measured using fluorescence imaging. Inhibitors of bitter taste receptor signaling were used to pharmacologically determine if this pathway was involved in the production of NO. RESULTS: A low-molecular-weight, heat, and protease-stabile product found in MRSA CM induced differential, NO synthase (NOS)-mediated NO production. This response varied markedly between individual patients. The MRSA-stimulated NO production was not dependent on 2 important components of bitter taste signaling: phospholipase C isoform β-2 or the transient receptor potential melastatin isoform 5 (TRPM5) ion channel. CONCLUSION: This study shows that a S. aureus product elicits an NO-mediated innate defense response in human upper airway epithelium. The active bacterial product is likely a small, nonpeptide molecule that triggers a pathway independent of bitter taste receptors. Patient variation in the NO response to MRSA product(s), potentially due to genetic differences, might play a role in pathophysiology of Gram-positive upper respiratory infections and/or pathogenesis of chronic rhinosinusitis.
BACKGROUND:Nitric oxide (NO) is an important antibacterial defense molecule produced by upper airway (sinonasal) epithelial cells. We previously showed that a bitter taste receptor expressed in airway epithelium detects quorum-sensing molecules secreted by Gram-negative bacteria and subsequently triggers bactericidal NO production. We hypothesized that the upper airway epithelium may also be able to detect the Gram-positive aerobe Staphylococcus aureus and mount an NO response. METHODS:Human sinonasal air-liquid interface (ALI) cultures were treated with methicillin-resistant S. aureus (MRSA)-conditioned medium (CM), and NO production was measured using fluorescence imaging. Inhibitors of bitter taste receptor signaling were used to pharmacologically determine if this pathway was involved in the production of NO. RESULTS: A low-molecular-weight, heat, and protease-stabile product found in MRSA CM induced differential, NO synthase (NOS)-mediated NO production. This response varied markedly between individual patients. The MRSA-stimulated NO production was not dependent on 2 important components of bitter taste signaling: phospholipase C isoform β-2 or the transient receptor potential melastatin isoform 5 (TRPM5) ion channel. CONCLUSION: This study shows that a S. aureus product elicits an NO-mediated innate defense response in human upper airway epithelium. The active bacterial product is likely a small, nonpeptide molecule that triggers a pathway independent of bitter taste receptors. Patient variation in the NO response to MRSA product(s), potentially due to genetic differences, might play a role in pathophysiology of Gram-positive upper respiratory infections and/or pathogenesis of chronic rhinosinusitis.
Authors: R Kyle Palmer; Karnail Atwal; Ivona Bakaj; Stacy Carlucci-Derbyshire; M Tulu Buber; Rok Cerne; Rosa Y Cortés; Heather R Devantier; Vincent Jorgensen; Aaron Pawlyk; S Paul Lee; Dennis G Sprous; Zheng Zhang; Robert Bryant Journal: Assay Drug Dev Technol Date: 2010-12 Impact factor: 1.738
Authors: J O Lundberg; T Farkas-Szallasi; E Weitzberg; J Rinder; J Lidholm; A Anggåard; T Hökfelt; J M Lundberg; K Alving Journal: Nat Med Date: 1995-04 Impact factor: 53.440
Authors: Ryan M Carey; Alan D Workman; Carol H Yan; Bei Chen; Nithin D Adappa; James N Palmer; David W Kennedy; Robert J Lee; Noam A Cohen Journal: Am J Rhinol Allergy Date: 2017-07-01 Impact factor: 2.467
Authors: Michael Hoggard; Brett Wagner Mackenzie; Ravi Jain; Michael W Taylor; Kristi Biswas; Richard G Douglas Journal: Clin Microbiol Rev Date: 2017-01 Impact factor: 26.132
Authors: Alan D Workman; Ryan M Carey; Michael A Kohanski; David W Kennedy; James N Palmer; Nithin D Adappa; Noam A Cohen Journal: Int Forum Allergy Rhinol Date: 2017-05-25 Impact factor: 3.858
Authors: Benjamin M Hariri; Sakeena J Payne; Bei Chen; Corrine Mansfield; Laurel J Doghramji; Nithin D Adappa; James N Palmer; David W Kennedy; Masha Y Niv; Robert J Lee Journal: Am J Rhinol Allergy Date: 2016-07 Impact factor: 2.467
Authors: Ryan M Carey; Bei Chen; Nithin D Adappa; James N Palmer; David W Kennedy; Robert J Lee; Noam A Cohen Journal: Int Forum Allergy Rhinol Date: 2016-08-10 Impact factor: 3.858